Skip Navigation


European Heart Journal Advance Access originally published online on November 10, 2006
European Heart Journal 2006 27(23):2742-2743; doi:10.1093/eurheartj/ehl350
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
27/23/2742    most recent
ehl350v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Stellbrink, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stellbrink, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Quick, easy, and safe? On the use of low-molecular-weight heparins in cardioversion of atrial fibrillation

Christoph Stellbrink

Department of Cardiology and Intensive Care Medicine, Bielefeld Medical Center, Teaching Hospital of the University of Münster, Teutoburger Strasse 50, 33604 Bielefeld, Germany

Corresponding author. Tel: +49 5215813401; fax: +49 5215813498. E-mail address: christoph.stel: brink@sk-bielefeld.de

This editorial refers to ‘The use of enoxaparin compared with unfractionated heparin for short-term antithrombotic therapy in atrial fibrillation patients undergoing transoesophageal echocardiography-guided cardioversion: Assessment of Cardioversion Using Transoesophageal Echocardiography (ACUTE) II randomized multicenter study’{dagger} by A.L. Klein et al., on page 2858

The first 10% of the full text of this article appears below.

Low-molecular-weight heparins (LMWHs) are gradually replacing unfractionated heparin (UFH) in several settings in cardiology and internal medicine. In most studies, LMWHs were either as effective as UFH or superior and had the additional advantage of the greater ease of subcutaneous application. Although earlier studies focused on the use of LMWHs in the venous vasculature, more recent studies have demonstrated some clinical advantages compared with UFH also in the arterial bed, e.g. in patients with unstable angina pectoris.1 Another clinical entity with the risk of arterial thrombo-embolism is atrial fibrillation (AF), an arrhythmia which not only shows a rising prevalence in recent years but is also associated with increased morbidity and mortality mainly . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

The use of enoxaparin compared with unfractionated heparin for short-term antithrombotic therapy in atrial fibrillation patients undergoing transoesophageal echocardiography-guided cardioversion: Assessment of Cardioversion Using Transoesophageal Echocardiography (ACUTE) II randomized multicentre study
Allan L. Klein, Susan E. Jasper, William E. Katz, Joseph F. Malouf, Linda A. Pape, Marcus F. Stoddard, Carolyn Apperson-Hansen, Elizabeth A. Lieber, and The ACUTE II Steering and Publications Committee For the ACUTE II Investigators
EHJ 2006 27: 2858-2865. [Abstract] [FREE Full Text]